drugset / Trial / NCT00225797

Efficacy and Safety of Oxmorphone Extended Release in Chronic Non-malignant Pain

NCT00225797

Phase 3 Completed 160 enrolled Endo USA Inc., a Keenova Therapeutics Company
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the analgesic efficacy and safety of oxymorphone extended release in non-cancer patients with chronic low back pain.

Timeline

Start
2004-11
Primary completion
Completion
2005-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Oxymorphone Small molecule Oral

Indications